Definition of postmenopausal status, age of the breast cancer patients and the outcome of aromatase inhibitors treatment

Breast

Volumn 17, Issue 5, 2008, Pages 433-435

  Aksoy, Sercan ^a   Dizdar, Omer ^a   Altundag, Kadri ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Age related effect; Aromatase inhibitor; Breast cancer; Postmenopausal status

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; FOLLITROPIN; GONADOTROPIN; LETROZOLE; LUTEINIZING HORMONE; METHOTREXATE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGE; AGED; AMENORRHEA; BREAST CANCER; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEEDBACK SYSTEM; FEMALE; GONADOTROPIN RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYSTERECTOMY; LETTER; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 53149135034     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2008.05.003     Document Type: Letter

References (6)

1. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139 Erratum in: Lancet 2002; 360:1520
2. Coates A.S., Keshaviah A., Thürlimann B., Mouridsen H., Mauriac L., Forbes J.F., et al. Five years of continuous letrozole versus tamoxifen as adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer: further analyses and update of BIG 1-98. Ann Oncol 17 Suppl. 9 (2006) ix93-ix94 [Abstract]
3. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
4. Coombes R.C., Paridaens R., Jassem J., Van de Velde C.J., Delozier T., Jones S.E., et al. First mature analysis of the Intergroup Exemestane Study. J Clin Oncol 24 (2006) LBA527 [Abstract]
5. Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., Amoroso D., Fini A., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23 (2005) 5138-5147
6. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271